Safety and Efficacy of Otaplimastat in Patients with Acute Ischemic Stroke Requiring tPA (SAFE‐TPA): A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Study

OBJECTIVE: Otaplimastat is a neuroprotectant that inhibits matrix metalloprotease pathway, and reduces edema and intracerebral hemorrhage induced by recombinant tissue plasminogen activator (rtPA) in animal stroke models. We aimed to assess the safety and efficacy of otaplimastat in patients receivi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jong S., Lee, Kyung Bok, Park, Jong‐Ho, Sung, Sang Min, Oh, Kyungmi, Kim, Eung‐Gyu, Chang, Dae‐il, Hwang, Yang Ha, Lee, Eun‐Jae, Kim, Won‐Ki, Ju, Chung, Kim, Byung Su, Ryu, Jei‐Man
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003891/
https://www.ncbi.nlm.nih.gov/pubmed/31721277
http://dx.doi.org/10.1002/ana.25644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003891/
https://www.ncbi.nlm.nih.gov/pubmed/31721277
http://dx.doi.org/10.1002/ana.25644

Ejemplares similares